Vialwirebiotech, curated
July 23, 2026, 3:11 AM
May 20, 2026
- 12:00 AM · FT — Pharmaceuticals12:00 AMBig Europe and Asian private equity health funds merge to defy AI disruption — FT — Pharmaceuticals
May 19, 2026
- 9:35 PM · STAT News9:35 PMSTAT+: 23andMe offers to connect users’ DNA data with medical records — STAT News
- 2:56 PM · Endpoints News2:56 PMAnother Paragon offshoot chooses reverse merger, this time for migraine drugs — Endpoints News
- 2:15 PM · Endpoints News2:15 PMAcceleron leaders and Westlake jumpstart new IPF biotech — Endpoints News
- 1:05 PM · The Guardian — Science1:05 PMArtificial eggshell comes first in attempt to revive giant flightless moa — The Guardian — Science
- 12:00 PM · BioWorld12:00 PMDaewoong nabs Innovo’s preclinical IBD asset in ₩663B deal — BioWorld
- 12:00 PM · BioWorld12:00 PMFosun secures rights to Aribio’s AR-1001 in potential $4.7B deal — BioWorld
- 12:00 PM · BioWorld12:00 PMCreate Medicines secures $122M for in vivo CARs — BioWorld
- 12:00 PM · BioWorld12:00 PMDegron closes $40M series A to advance molecular glue degraders — BioWorld
- 12:00 PM · BioWorld12:00 PMVincentage’s oral GLP-1 meets phase III obesity endpoints — BioWorld
- 11:22 AM · Endpoints News11:22 AMQ&A: Novo research chief Petersen says streamlined R&D speeds discovery — Endpoints News
- 11:19 AM · Endpoints News11:19 AMWave aims for monthly dosing with RNA editing treatment for AATD — Endpoints News
- 9:00 AM · BioWorld9:00 AMBiocryst’s BCX-17725 as new approach for Netherton syndrome — BioWorld
- 9:00 AM · BioWorld9:00 AMChina’s NMPA clears KAT6 inhibitor SYH-2095 for clinic — BioWorld
- 9:00 AM · BioWorld9:00 AMKorro Bio nominates new candidate for AATD — BioWorld
- 9:00 AM · BioWorld9:00 AMIksuda and UCL report new B7-H3-targeting ADCs — BioWorld
- 9:00 AM · BioWorld
- 8:56 AM · Drug Discovery World8:56 AMOutSee receives Discovery Award from Longitude Prize on ALS — Drug Discovery World
- 7:13 AM · Endpoints News7:13 AMRelay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study — Endpoints News
- 6:18 AM · Endpoints News6:18 AMBioMarin's rare disease therapy shows no clinical benefit in Phase 3 test — Endpoints News
- 5:45 AM · Pharmaceutical Technology5:45 AMVERTANICAL’s VER-01 gains FDA breakthrough status for low back pain — Pharmaceutical Technology
- 5:16 AM · Pharmaceutical Technology5:16 AMRegeneron signs $2.32bn deal with Parabilis for Helicon conjugates — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMNew Fact Sheet: Liver organoid platform for predictive hepatotoxicity assessment — Drug Discovery World
May 18, 2026
- 6:08 PM · STAT News6:08 PMSTAT+: Maryland state affordability board places a price cap on Ozempic — STAT News
- 5:29 PM · TechCrunch
- 2:21 PM · Endpoints News2:21 PMAmgen stands by rare disease drug Tavneos amid Japan liver toxicity report — Endpoints News
- 12:00 PM · BioWorld12:00 PMRegeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis — BioWorld
- 12:00 PM · BioWorld12:00 PMUS Supreme Court swats down several biopharma IRA challenges — BioWorld
- 12:00 PM · BioWorld12:00 PMBoston Sci invests $1.5B in Mirus, gains option for TAVR system — BioWorld
- 10:44 AM · Endpoints News10:44 AMMerck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule — Endpoints News
- 9:00 AM · BioWorld9:00 AMMD Anderson gains IND nod for CD94-targeted CAR T therapy — BioWorld
- 9:00 AM · BioWorld9:00 AMGPX-002 restores β-cell function in a diabetes model — BioWorld
- 9:00 AM · BioWorld9:00 AMHarbour Biomed’s LET-003 shows promise for obesity — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMIND-enabling studies of adult RPE stem cell product for dry AMD — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMCytiva’s transcient cell line receives FDA AMT designation — Drug Discovery World
- 6:34 AM · Endpoints News6:34 AMRegeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3 — Endpoints News
- 6:01 AM · Endpoints News6:01 AMFDA approves AstraZeneca’s baxdrostat for certain patients with hypertension — Endpoints News
- 6:00 AM · Drug Discovery World6:00 AMGSK signs agreement to streamline clinical trials — Drug Discovery World
- 6:00 AM · Pharmaceutical Executive6:00 AM<![CDATA[FDA’s New Pilot Program and Real-Time Review of Clinical Data]]> — Pharmaceutical Executive
- 5:00 AM · Drug Discovery World5:00 AMMediar selects Qureight to support systemic sclerosis trial — Drug Discovery World
- 3:49 AM · Pharmaceutical Technology3:49 AMFDA approves Enhertu for two HER2-positive early breast cancer indications — Pharmaceutical Technology